Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs
1. BMY beat first-quarter estimates, raising 2025 revenue guidance. 2. Cost-cutting plans aim to reduce $2 billion by 2027. 3. Cobenfy underperformed in trials, affecting sales forecasts significantly. 4. Eliquis sales declined; expected to lose exclusivity by 2028. 5. Growth portfolio shows strength, with $5.56 billion in revenues.